The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > October 1, 2025
Daily News
October 1, 2025
- Takeda to Reevaluate Osaka Plasma Facility Plan as Costs Mount
October 1, 2025
- SSP to Roll Out Pharmacist Training Ahead of OTC Cialis Launch in Japan
October 1, 2025
- Policy Veterans’ Group Calls for Inflation-Linked Drug Pricing in FY2026 Reform
October 1, 2025
- Heartseed, Novo Nordisk End Global Cell Therapy Pact
October 1, 2025
- Dalton Drops ASKA Stake Increase Plan, Slams Firm’s “Self-Preservation”
October 1, 2025
- Japan Will Receive MFN Status on US Drug Tariffs: Akazawa
October 1, 2025
- Nxera Earns US$10 Million Milestone from AbbVie in Neurology Deal
October 1, 2025
- Santen, RemeGen Win China Filing Acceptance for RC28-E in DME
October 1, 2025
- Ono Files SK Bio’s Epilepsy Med Cenobamate in Japan
October 1, 2025
- MHLW Council Clears Public Knowledge Filing for MabCampath in T-PLL
October 1, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…